Rein Therapeutics

Yahoo Finance • 3 days ago

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09... Full story

Yahoo Finance • 25 days ago

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis

AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonar... Full story

Yahoo Finance • last month

Rein Therapeutics files to sell 10M shares of common stock for holders

* Rein Therapeutics (NASDAQ:RNTX [https://seekingalpha.com/symbol/RNTX]) filed to sell 10M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10383745] MORE ON AILERON THERAPEUTICS * Rein Therapeutics... Full story

Yahoo Finance • 2 months ago

UK regulator approves Rein Therapeutics' phase 2 trial for IPF drug

LONDON - Rein Therapeutics (NASDAQ:RNTX), a clinical-stage biotech company currently valued at $26 million, announced Tuesday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of its Phase... Full story

Yahoo Finance • 2 months ago

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fi... Full story

Yahoo Finance • 2 months ago

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary... Full story